Sandeep Dutta
19Patents
9h-index
29Co-inventors
68Inventor score
Filing activity: Dec 22, 2000 → Feb 14, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8466159B2 | Methods for treating HCV | Human Necessities | 24 | Active |
| US6713086B2 | Controlled release formulation of divalproex sodium | Human Necessities | 22 | Expired |
| US8492386B2 | Methods for treating HCV | Physics | 21 | Active |
| US8435523B2 | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability | Chemistry; Metallurgy | 17 | Active |
| US8809265B2 | Methods for treating HCV | Human Necessities | 15 | Active |
| US8685984B2 | Methods for treating HCV | Physics | 15 | Active |
| US8680106B2 | Methods for treating HCV | Human Necessities | 13 | Active |
| US8993578B2 | Methods for treating HCV | Physics | 11 | Active |
| US8969357B2 | Methods for treating HCV | Human Necessities | 11 | Active |
| US6528090B2 | Controlled release formulation of divalproex sodium | Human Necessities | 9 | Expired |
| US6720004B2 | Controlled release formulation of divalproex sodium | Human Necessities | 6 | Expired |
| US8853176B2 | Methods for treating HCV | Human Necessities | 6 | Active |
| US6511678B2 | Controlled release formulation of divalproex sodium | Human Necessities | 3 | Expired |
| US10286029B2 | Method for treating HCV | Human Necessities | 1 | Active |
| US9447181B2 | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability | Chemistry; Metallurgy | 0 | Active |
| US8680048B2 | Methods for treating HCV | General | 0 | Revoked |
| US9452194B2 | Methods for treating HCV | Human Necessities | 0 | Active |
| US11484534B2 | Methods for treating HCV | Human Necessities | 0 | Active |
| US8222278B2 | Treatment of attention-deficit/hyperactivity disorder | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.